Skip to main content
OpenTrials
Completed

NCT Number: NCT05526326

OrganOx Metra® New Enrollment PAS

The objective of the OrganOx metra® New Enrollment Post-Approval Study is to collect data on the post-transplant clinical outcomes of DBD and DCD donor livers preserved and assessed on the OrganOx according to the current indications for use in the real-world setting.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Medstar Georgetown University Hospital, Washington D.C., District of Columbia, United States

Loading trial locations.

About this study

The OrganOx metra® New Enrollment Post-Approval Study is a multi-site, single arm, unblinded post-approval study that will enroll deceased DBD or DCD donor liver and adult liver transplant recipients according to the current indication and that match the eligibility criteria below.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is 18 years of age or greater
  • Subject is registered as an active recipient on the UNOS waiting list for liver transplantation
  • Subject, or legally authorized representative, is able and willing to give informed consent and HIPAA authorization
  • Subject is able and willing to comply with all study requirements (in the opinion of the Investigator)

Exclusion criteria

  • Subject requiring all of the following at the time of transplantation:
  • Oxygen therapy via a ventilator/respirator
  • Inotropic support
  • Renal replacement therapy
  • Subject has acute/fulminant liver failure (UNOS status 1A)
  • Subject planned to undergo simultaneous transplantation of more than one organ (e.g., liver and kidney) from the same liver donor
  • Subject is pregnant (as confirmed by urine or serum pregnancy test) or nursing
  • Concurrent enrollment in another clinical study. Subjects enrolled in clinical studies or registries where only measurements and/or samples are taken (no test device or test drug) are allowed to participate.

Treatment and study plan

Transplant with normothermic machine perfused (NMP) donor liver

Device

The enrolled recipient will receive a DBD or DCD donor liver that underwent normothermic machine perfusion with the OrganOx metra®

Other names: OrganOx metra® normothermic machine perfusion

Primary outcomes

  1. Adverse biliary-related events

    Time frame: 12-months post-transplant

    Adverse biliary-related events as measured by biliary complications

Secondary outcomes

  1. Graft survival

    Time frame: 12-months post-transplant

    Liver graft survival post-liver transplant as measured by the number of subjects needing a re-transplant

  2. Subject survival

    Time frame: 12-months post-transplant

    Subject survival post-liver transplant

Sponsors and collaborators

Lead sponsor

OrganOx Ltd.

Industry

Registry information

Official study title

OrganOx Metra® New Enrollment Post-Approval Study

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Sep 2, 2022
Registry last updated
Apr 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.